These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

936 related items for PubMed ID: 9209739

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Natural killer cell numbers and activity in mobilized peripheral blood stem cell grafts: conditions for in vitro expansion.
    Silva MR, Parreira A, Ascensão JL.
    Exp Hematol; 1995 Dec; 23(14):1676-81. PubMed ID: 8542964
    [Abstract] [Full Text] [Related]

  • 7. Immunomodulation of early engrafted natural killer cells with interleukin-2 and interferon-alpha in autologous stem cell transplantation.
    Porrata LF, Inwards DJ, Lacy MQ, Markovic SN.
    Bone Marrow Transplant; 2001 Oct; 28(7):673-80. PubMed ID: 11704790
    [Abstract] [Full Text] [Related]

  • 8. Expansion and manipulation of natural killer cells in patients with metastatic cancer by low-dose continuous infusion and intermittent bolus administration of interleukin 2.
    Soiffer RJ, Murray C, Shapiro C, Collins H, Chartier S, Lazo S, Ritz J.
    Clin Cancer Res; 1996 Mar; 2(3):493-9. PubMed ID: 9816195
    [Abstract] [Full Text] [Related]

  • 9. Activated peripheral blood mononuclear cells from patients receiving subcutaneous interleukin-2 following autologous stem cell transplantation prolong survival of SCID mice bearing human lymphoma.
    Katsanis E, Weisdorf DJ, Miller JS.
    Bone Marrow Transplant; 1998 Jul; 22(2):185-91. PubMed ID: 9707028
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Subcutaneous versus intravenous low-dose IL-2 therapy after autologous transplantation: results of a prospective, non-randomized study.
    López-Jiménez J, Pérez-Oteyza J, Munoz A, Parra C, Villalón L, Ramos P, Maldonado M, García-Laraña J, Otheo E, Roldán E, García-Avello A, Odriozola J.
    Bone Marrow Transplant; 1997 Mar; 19(5):429-34. PubMed ID: 9052907
    [Abstract] [Full Text] [Related]

  • 12. Interleukin-2-activated hematopoietic stem cell transplantation for breast cancer: investigation of dose level with clinical correlates.
    Meehan KR, Verma UN, Cahill R, Frankel S, Areman EM, Sacher RA, Foelber R, Rajagopal C, Gehan EA, Lippman ME, Mazumder A.
    Bone Marrow Transplant; 1997 Oct; 20(8):643-51. PubMed ID: 9383227
    [Abstract] [Full Text] [Related]

  • 13. A phase I study of ultra low dose interleukin-2 and stem cell factor in patients with HIV infection or HIV and cancer.
    Shah MH, Freud AG, Benson DM, Ferkitich AK, Dezube BJ, Bernstein ZP, Caligiuri MA.
    Clin Cancer Res; 2006 Jul 01; 12(13):3993-6. PubMed ID: 16818697
    [Abstract] [Full Text] [Related]

  • 14. Immunotherapy with interleukin 2 with or without lymphokine-activated killer cells after autologous bone marrow transplantation for malignant lymphoma: a feasibility trial.
    Benyunes MC, Higuchi C, York A, Lindgren C, Thompson JA, Buckner CD, Fefer A.
    Bone Marrow Transplant; 1995 Aug 01; 16(2):283-8. PubMed ID: 7581149
    [Abstract] [Full Text] [Related]

  • 15. Synergistic interleukin-18 and low-dose interleukin-2 promote regression of established murine neuroblastoma in vivo.
    Redlinger RE, Mailliard RB, Lotze MT, Barksdale EM.
    J Pediatr Surg; 2003 Mar 01; 38(3):301-7; discussion 301-7. PubMed ID: 12632339
    [Abstract] [Full Text] [Related]

  • 16. Daily subcutaneous injection of low-dose interleukin 2 expands natural killer cells in vivo without significant toxicity.
    Meropol NJ, Porter M, Blumenson LE, Lindemann MJ, Perez RP, Vaickus L, Loewen GM, Creaven PJ, Wilkes KA, Giedlin MA, Caligiuri MA.
    Clin Cancer Res; 1996 Apr 01; 2(4):669-77. PubMed ID: 9816217
    [Abstract] [Full Text] [Related]

  • 17. Clinical and immunomodulatory effects of combination immunotherapy with low-dose interleukin 2 and tumor necrosis factor alpha in patients with advanced non-small cell lung cancer: a phase I trial.
    Yang SC, Grimm EA, Parkinson DR, Carinhas J, Fry KD, Mendiguren-Rodriguez A, Licciardello J, Owen-Schaub LB, Hong WK, Roth JA.
    Cancer Res; 1991 Jul 15; 51(14):3669-76. PubMed ID: 1648441
    [Abstract] [Full Text] [Related]

  • 18. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
    Keever CA, Pekle K, Gazzola MV, Collins NH, Bourhis JH, Gillio A.
    J Immunol; 1989 Nov 15; 143(10):3241-9. PubMed ID: 2809200
    [Abstract] [Full Text] [Related]

  • 19. Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells.
    van Besien K, Margolin K, Champlin R, Forman S.
    Cancer J Sci Am; 1997 Dec 15; 3 Suppl 1():S54-8. PubMed ID: 9457395
    [Abstract] [Full Text] [Related]

  • 20. Effects of escalating doses of recombinant human interleukin-2 in correcting functional T-cell defects following autologous bone marrow transplantation for lymphomas and solid tumors.
    Bosly A, Guillaume T, Brice P, Humblet Y, Staquet P, Doyen C, Chatelain B, Franks CR, Gisselbrecht C, Symann M.
    Exp Hematol; 1992 Sep 15; 20(8):962-8. PubMed ID: 1354620
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 47.